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Only a minority of hepatitis B patients benefit
from current treatment strategies. Standard alpha
interferon (IFN) therapy is effective in about one
third of patients; prolongation increases the re-
sponse rate to a maximum of 40% of patients (1,
2). The response rate depends mainly on baseline
characteristics (3). Although lamivudine results in
serological, biochemical and histological improve-
ment in 60–70% of patients, viral clearance is
achieved in only 16% of patients at 1 year of ther-
apy (4, 5). Prolongation of lamivudine therapy be-
yond 1 year is hampered by the increasing occur-
rence of lamivudine-resistant mutants, reaching
50% after 2 years (4, 6). Although lamivudine and
interferon monotherapy clearly has a role in anti-
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viral therapy for chronic hepatitis B (CHB), their
present therapeutic achievements leave sufficient
room for the development of new therapeutic
strategies.
The efficacy of hepatitis B immunoglobulin
(HBIG) in passive immune prophylaxis of ortho-
topic liver transplant (OLT) patients has been re-
ported (7, 8). In a vaccination trial it has been
shown that [HBsAb–HBsAg] complexes enhance
the proliferative response of human HBsAg-spe-
cific T-cell clones, resulting in a therapeutic effect
on chronic hepatitis B infection (9). Since im-
munotherapy in CHB with passive immunization
with anti-HBs was attempted by Reed et al.
using polyclonal HBIG in 1973 and with mono-
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clonal antibodies by Lever et al. in 1987, no tri-
als of anti-HBs have been performed for the
treatment of CHB (10, 11). We therefore
attempted immunotherapy with Mab in the ten
patients reported here.
Tuvirumab (Mab) is a human monoclonal anti-
body of the IgG1 subclass. It is produced by a
transfectoma cell line, a recombinant mouse cell
line (SP2/0), which is transfected with the genetic
material of a human B lymphocyte of an HBV-
vaccinated patient. Regarding binding site and
binding affinity with HBsAg, Tuvirumab is identi-
cal to OST 577, produced by a ‘trioma’ cell line,
for which clinical pilot studies were performed in
OLT patients, (12, 13). Both antibodies have the
same genetic code from the same peripheral blood
lymphocyte. Mab recognizes the ‘a’-determinant of
the hepatitis B surface antigen. The ‘a’-determi-
nant is the most stable part of the hepatitis B virus
and one of the major neutralizing epitopes. Anti-
‘a’ antibodies are protective against almost all
known subtypes of the hepatitis B virus (14, 15).
The binding activity of Mab is 200-fold higher
compared with serum-derived polyclonal anti-
bodies (HBIG) (16).
In a phase II trial, the safety and efficacy of
Mab were investigated. The trial was stopped
prematurely after 10 patients had been treated with
the monoclonal antibody for at least 4 weeks. The
results are presented here.
Patients and methods
Patients
Fifteen patients, eight IFN nonresponders and
seven IFN naive, were included in this trial after
giving their informed consent. All patients were
over 18 years of age and suffered from chronic
hepatitis B, defined as HBsAg and HBeAg posi-
tivity in serum lasting for at least 6 months, in-
creased alanine aminotransferase (ALT) (50–400
U/l) for the last 6 months before study entry, de-
tectable serum HBV-DNA (liquid hybridization
test), and a histological diagnosis of chronic
hepatitis (portal inflammation, hepatocyte ne-
crosis).
Exclusion criteria were: Asian origin, pregnant
or lactating women, detectable serum HBeAb, co-
infection with HAV, HCV, HDV, HIV, fulminant,
alcoholic or drug-induced hepatitis or decompen-
sated liver disease. For safety reasons, patients
were not included if there was a history of periart-
eriitis nodosa, serum sickness, psoriasis, creatinine
.1.5 times upper limit of normal, proteinuria,
micro-hematuria, major organic dysfunction or
contraindication to interferon.
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Medication
Patients were stratified for previous IFN therapy
and randomly assigned to one of the following
groups:
O Mab treatment group (nΩ4);
O MabpiIFN treatment group (combination
group) (nΩ6);
O IFN treatment group (only IFN naive) (nΩ3):
O Untreated control group (only IFN nonre-
sponders) (nΩ2).
Interferon a-2b (IntronTM A, Schering-Plough)
was given according to the standard regimen, i.e.
5–10 MU tiw intracutaneously for 16 weeks, and
was not administered on the same day as Mab in
the combination group.
Mab is a lyophilisate, which has to be reconsti-
tuted with 10 ml sterile water before administration.
After reconstitution, the drug was given intra-
venously in 250 ml 0.9% NaCl over a 30-min period.
During the first 2 weeks (escalation phase) Mab
was given every 2–3 days according to a fixed dosing
schedule: 20 mg–20 mg–40 mg–40 mg–80 mg–80 mg
(20 mg Mab corresponds to about 360 000 IU anti-
HBs HBIG). The dosing schedule was based on
safety and efficacy data collected in a pilot study
with OST-577 (14). The dose escalation should re-
sult in a step-wise reduction of the HBsAg serum
level and should therefore minimize potential ad-
verse events caused by the formation of insoluble
[HBsAg–HBsAb] complexes. The aim of this escala-
tion phase was to neutralize circulating HBsAg, re-
sulting in free circulating anti-HBs.
In week 3, the maintenance phase, dosing was
individualized in order to maintain free anti-HBs
levels in the blood. In this phase anti-HBs serum
levels were measured every 2 weeks. Further Mab
doses were administered depending on the anti-
HBs levels, according to the following schedule:
O serum anti-HBs level .5 mg/ml (corresponds to
about 90 000 IU/l HBIG): no further Mab ad-
ministration for the next 2 weeks;
O serum anti-HBs level .1 mg/ml (corresponds to
about 18 000 IU/l HBIG) but ,5 mg/ml: 1 single
dose of 80 mg Mab or of the individual maxi-
mum tolerated dose (MTD, see critical events)
for the next 2 weeks;
O serum anti-HBs level ,1 mg/ml: 5 doses (every
2 days) of 80 mg Mab or of the MTD for the
next 2 weeks. If free serum anti-HBs levels were
not reached after this frequent dosing, treat-
ment was stopped for reasons of feasibility.
Critical events
From the results of the above-mentioned pilot
study with OST-577, it was anticipated that the de-
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velopment of adverse events in patients receiving
Mab would be mainly related to the formation of
insoluble [HBsAg–HBsAb] complexes. For safety
reasons critical events were defined: anaphylactic
reactions type I, cardiovascular reaction during or
within 3 h after infusion (shock index .1.2, hyper-
tension), generalized dermatological reactions, se-
vere arthralgia, shaking chills/rigors, increase in
body temperature .1.5æC (2.5æF). The following
laboratory parameters were considered critical ad-
verse events: micro-hematuria, proteinuria, serum
creatinine and urea .150% of initial value, a rel-
evant decrease in serum albumin or an increase of
serum ALT 5¿ higher initial value or .800 IU/l.
If critical events occurred during the therapy,
Mab dosing was stopped until the event resolved,
and afterwards therapy was continued with a 50%
reduced dose, which was considered the individual
maximum tolerated dose (MTD). Frequency of
dosing of MTD was as described above.
Laboratory methods
The primary endpoint of the study was the devel-
opment and maintenance of free anti-HBs levels.
Secondary reduction of HBsAg and changes in
HBV DNA and ALT were measured. All serum
samples were stored at ª20æC, and HBV markers
were assessed centrally. HBV-DNA was quantified
by liquid hybridization (Digene-Murex, UK).
HBeAg and anti-HBe (qualitatively) were meas-
ured using ENZYMUNTM tests (Boehringer
Mannheim, Germany). Anti-HBs (mg/ml) was de-
tected with a specific double-antigen ELISA (en-
zyme-linked immunosorbent assay) using biotinyl-
ated wild-type HBsAg, which was immobilized on
a streptavidin-coated tube, as the solid phase. The
bound antibodies were detected by binding to a
horseradish peroxidase conjugated wild-type
HBsAg catalyzing the formation of a colored
product (ENZYMUNTM tests, Boehringer Mann-
heim, Germany). HBsAg (U/ml) was measured by
a standard MEIA (microparticle enzyme immuno-
Table 1. Baseline characteristics of patients. Data are expressed as median (min–max)
Mab MabpiIFN IFN Untreated
treatment group treatment group treatment group control group
Patients 1 IFN naive 3 IFN naive 3 IFN naive 2 IFN nonresponders
3 IFN nonresponders 3 IFN nonresponders
Age (years) 55 (39–63) 39 (19–46) 37 (24–48) 29 (28–30)
Gender (male/female) 4/0 4/2 2/1 1/1
HBsAg (U/ml) 36 750 (1740–72 000) 2835 (2200–22 200) 43 200 (6200–73 000) 3550 (900–6200)
HBV DNA (pg/ml) 2149 (467–6130) 152 (8–5065) 3755 (2641–33 220) 556 (67–1045)
ALT (U/l) 90 (65–116) 100 (27*–199) 166 (144–199) 132 (34*–230)
* Protocol violator.
IFN, interferon. ALT, alanine aminotransferase.
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assay) (Abbott Imx System). A monoclonal
HBsAg-antibody that specially binds HBsAg from
serum is immobilized to microparticles. The bound
HBsAg is detected with biotinylated polyclonal
goat anti-HBs and a polyclonal rabbit anti-biotin
antibody conjugated with alkaline phosphatase
catalyzes the formation of a fluorescent product.
The study was performed according to good
clinical practice guidelines and the Declaration of
Helsinki. All local Medical Ethics Committees ap-
proved the protocol.
Results
Fifteen patients were included in the trial: ten re-
ceived Mab (four monotherapy and six combi-
nation therapy with interferon). Baseline charac-
teristics are listed in Table 1.
Safety
No drug-related serious adverse event was ob-
served. A summary of all adverse events probably
or possibly related to Mab is demonstrated in
Table 2. Eight out of ten patients experienced ad-
verse events probably related to the administra-
tion of Mab. In seven patients, four patients in
the Mab group and three patients in the combi-
nation group, critical adverse events occurred.
Shaking chills/rigors partially combined with fe-
ver were reported 5 times for three patients, one
in the combination group and two in the Mab
group. Proteinuria and micro-hematuria were re-
ported for three patients, two in the combination
group and one in the Mab group. Flu-like syn-
drome was reported twice in one patient of the
combination group.
Shaking chills/rigors, fever and flu-like syn-
drome resolved within hours after infusion, one
patient received an H2-antagonist and in some
cases paracetamol was used. Proteinuria and
micro-hematuria resolved within a few days after
withdrawal of therapy. According to the study pro-
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Table 2. Summary of adverse events (AE) probably or possibly related to Mab
Critical AE
AE Critical AE (temp. stop of treatmentpi
(no measures) (dose reduction) dose reduction) Total AE
Chills 1 3 0 4
Fever 0 2 0 2
Abdominal pain 1 0 0 1
Tinnitus 1 0 0 1
Arthralgia 1 0 0 1
Syncope 1 0 0 1
Dyspnea 2 0 0 2
Flu-like syndrome 0 2 0 2
Lower back pain 1 0 0 1
Leukopenia 1 0 0 1
Proteinuria 1 0 3 4
Micro-hematuria 0 0 1 1
tocol, all seven patients were rechallenged with a
50% reduced Mab dose (MTD) after the events re-
solved. No further critical event was observed.
Efficacy
Mab was administered over a period of 27–59
days. In eight out of ten cases Mab was discon-
tinued prematurely according to the study proto-
col, because a frequent treatment of 5 infusions in
2 weeks during one cycle in the maintenance phase
did not result in free anti-HBs serum levels. One
patient was withdrawn from further treatment as
scheduled prematurely; no free anti-HBs was de-
tectable. Seven of these eight patients received a
reduced Mab dose (MTD) because of critical
events: 40 mg (nΩ3) and 20 mg (nΩ4). In two pa-
tients the administration of Mab was withdrawn
prematurely because the study was stopped; in one
patient anti-HBs was detectable.
Fig. 1. HBsAg levels (U/ml) measured before start of therapy,
on day 14, 27, at the end of treatment and end of follow up after
administration of Mab in the monotherapy (O) or combination
therapy (¿) group.
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Thus, none of the patients had a sustained clear-
ance of serum HBsAg with the described dose regi-
men. In nine out of ten patients treated with Mab
the treatment was stopped prematurely because
free anti-HBs levels could not be achieved.
HBsAg levels were reduced by at least 50% in all
ten patients during Mab treatment in both groups
(monotherapy and combination). Fig. 1 shows the
individual HBsAg curves. In three out of six pa-
tients in the combination group HBsAg levels were
transiently decreased to background levels on vari-
ous occasions, coinciding with free anti-HBs levels
in the serum. A relapse of HBsAg above pretreat-
ment levels after stopping treatment was observed
in two patients in the Mab group. The relative
changes of HBsAg serum levels for these ten pa-
tients at the end of therapy and end of follow-up
(EFU) are demonstrated in Fig. 2.
In the IFN and untreated control group HBsAg
levels fluctuated considerably. A temporary drop
Fig. 2. The maximal (max) drop in HBsAg (U/ml) and the per-
centage decrease in HBsAg at the end of follow-up (EFU) per
patient in the monotherapy (Mab) and combination (Mab
piIFN) group. In seven patients HBsAg levels increased again
at the EFU, in three patients minimal HBsAg levels were
reached at the EFU.
Efficacy and safety of Tuvirumab
of at least 50% was observed in two out of five
patients, while in another patient HBsAg increased
by 100%.
With respect to the HBV-DNA levels, three pa-
tients in the combination group exhibited a loss of
HBV-DNA after about 1 week, which was main-
tained until the end of follow-up, i.e. 8–46 weeks
after start of treatment, IFN was continued in all
cases during this period. HBeAg seroconversion
was seen in two of these three patients. More than
50% reduction of HBV DNA was observed in the
other three patients treated with combination ther-
apy. In the other treatment groups no clinically rel-
evant changes in HBV DNA levels were observed.
ALT decreased by 30% in the patients treated
with Mab, which implies normalization of ALT in
two out of ten patients, one patient treated with
combination therapy and one with monotherapy.
No clinically relevant changes in ALT were ob-
served in the untreated and IFN-treated patients,
which was expected considering the short obser-
vation period.
Discussion
The mode of action of passive immunization in
hepatitis B patients is only partially known.
Monoclonal or polyclonal antibodies bind HBsAg,
i.e. virions, filaments and spheres that are circu-
lating as free particles in the blood or that are pre-
sented at the surface of cells. Consequently, the in-
fection of noninfected cells via circulation should
be inhibited. This assumption is supported by re-
sults generated during the administration of HBIG
in OLT patients and by results of HBIG treatment
for interruption of vertical transmission of the vi-
rus in neonates of HBsAg-positive mothers and
after needle-stick injuries (8, 17, 18).
Antibodies might have an indirect effect on cel-
lular immune response via ADCC (antibody de-
pendent cellular toxicity) by binding and activation
of NK cells, or other so far only incompletely
understood mechanisms. This hypothesis is sup-
ported by results from a vaccination trial, in which
the administration of [HBsAg–HBsAb] complexes
resulted in an enhanced proliferative response of
human HBsAg-specific T-cell clones, producing a
therapeutic effect in CHB patients (9). The concept
of immune complexes acting as a strong immune
stimulus for humoral immunity is further sup-
ported by experimental work (19). Furthermore,
coating of HBV-infected hepatocytes may stimu-
late the leukocyte-mediated phagocytosis (opsoniz-
ation) (20). In vivo and in vitro (mice model) IgG-
anti-HBs can stimulate T-helper cells to produce
lymphokines, which promote antibody synthesis
by autologous B lymphocytes (21). In chronic
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hepatitis B patients, excess circulating HBsAg may
paralyze the immune system, enabling the virus to
survive (high dose tolerance induction) (7). A re-
duction of serum HBsAg therefore might result in
a reactivation of the endogenous immune system
(15).
In this trial the most important finding as to ef-
ficacy was that sustained clearance of serum
HBsAg was not achieved in any of the Mab-treated
patients using the described dose regimen. In nine
out of ten patients treated with Mab the treatment
was stopped prematurely because the primary goal
of reaching and maintaining free anti-HBs levels
could not be achieved. On the other hand, it could
be shown that Mab recognized and cleared HBsAg
from the serum to various degrees. Only in the
combination therapy group serum did HBsAg de-
crease transiently to background levels in three pa-
tients. Theoretically, this may also reflect a lower
production of HBsAg particles because of a reduc-
tion of infected hepatocytes in these patients.
However, in case of stimulation of the cellular im-
mune system, one would expect an elevation of
serum transaminases. None of the ten patients
treated with Mab showed a peak in transaminase
activity during the treatment or follow-up.
Only in the combination group was serum
HBsAg decreased transiently to background levels
in three patients. However, it has to be noted that
these three patients had relatively low pretreatment
HBsAg levels. In general, patients with lower base-
line HBsAg levels had a better response. Therefore,
an additional effect of IFN on HBsAg serum levels
in the combination group, especially in the first
weeks of therapy, is unlikely.
With respect to the HBV-DNA, however, it
seemed that the combination of Mab with IFN is
clearly superior to each compound alone. Only in
the combination group did three patients show a
sustained loss of HBV-DNA. In two of these, this
was even combined with an HBeAg seroconversion
when the study was stopped, about 8 to 46 weeks
after the start of treatment. Since IFN treatment
was continued in all cases, even if Mab treatment
was stopped prematurely, it is not possible to dis-
cern the relative contribution of the two com-
pounds to this positive development, i.e. it cannot
be ruled out that this simply reflects the well-
known effect of IFN.
The critical adverse events seem to be caused by
the development of insoluble [HBsAg–HBsAb]
complexes after Mab infusion. This indicates again
that the antibody is highly effective in binding the
antigen and furthermore that the chosen dosing
schedule was not sufficient in terms of a safe neut-
ralization of HBsAg. There was no predictor for
the development of these critical events. However,
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it is likely that after reduction of HBsAg following
Mab administration the amounts of antigen and
antibody draw near an ‘equivalence range’, com-
bined with an increased risk of development of in-
soluble antigen-antibody complexes.
With respect to the very limited sample size and
treatment/observation period, it is obviously not
possible to judge whether the described effects on
serum markers of CHB could potentially be trans-
lated into clinically meaningful results if the treat-
ment could be maintained by the use of an alterna-
tive regimen. The most appropriate approach ap-
pears to be a substantial reduction of HBsAg
before initiating the Mab treatment and a main-
tained blocking of viral transcription, e.g. by pre-
and concomitant treatment with nucleoside anal-
ogs. This may prevent the occurrence of insoluble
[HBsAg–HBsAb] complexes and may facilitate the
complete clearance of HBsAg and viral particles
by the monoclonal antibody.
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